Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17282047 | 0.82 | SLC6A2 (0.56) | OPRM1AGTR2 | |
| SCHEMBL5036916 | 0.81 | OPRM1 (0.45) | OPRM1PKMMAOAMAOBNISCH | |
| SCHEMBL5036802 | 0.79 | DCUN1D1 (0.47) | OPRM1PKMMAOAMAOB | |
| SCHEMBL2799018 | 0.76 | AGTR2 (0.43) | OPRM1PKMMAOAMAOBNISCH | |
| SCHEMBL17281931 | 0.76 | CHIA (0.53) | OPRM1PKM | |
| SCHEMBL22289769 | 0.75 | C5AR1 (0.46) | OPRM1PKMMAOAMAOBNISCH | |
| SCHEMBL11999861 | 0.75 | HSD11B1 (0.49) | OPRM1PKMMAOAMAOBNISCH | |
| SCHEMBL13050349 | 0.73 | GRIN2B (0.49) | OPRM1AGTR2 | |
| SCHEMBL21569748 | 0.72 | CYP2C19 (0.58) | — | |
| SCHEMBL340688 | 0.72 | PKM (0.57) | OPRM1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | OPRM1 511/4885PKM 4302/4885MAOA 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.